The idea of using psychedelics to treat depression might sound like something from a sci-fi novel, but UK researchers have been testing it in real patients since 2022. So far, the results are hard to ignore. In small clinical trials, people with severe depression who took psilocybin—the psychoactive compound in “magic mushrooms”—showed rapid and lasting improvements in their symptoms after just two or three sessions, combined with therapy. One study at Imperial College London found that 22 out of 30 patients no longer met the criteria for depression three weeks after treatment. Another trial at King’s College London reported similar findings, with many patients still feeling better six months later. The NHS isn’t jumping to conclusions, but it’s now seriously considering whether psilocybin therapy could become part of its mental health toolkit. That’s a big shift from just a few years ago, when psychedelics were almost entirely off-limits for medical use in the UK. In 2023, the Home Office reclassified psilocybin from a Class A drug to Schedule 2, making it easier for researchers to conduct trials. This move acknowledged the growing body of evidence that these substances might have real therapeutic value when used correctly. But it’s not all smooth sailing. Psilocybin isn’t a magic cure, and it doesn’t work for everyone. The trials are still small, and the long-term effects aren’t fully understood. Patients often experience intense emotional and perceptual changes during sessions, which can be overwhelming without proper support. That’s why these treatments always include guided therapy before, during, and after the psychedelic experience. ## Could this change how depression is treated in the UK? The NHS treats depression with antidepressants and talking therapies, but for many patients, these options don’t work well enough or take weeks to show results. Psilocybin therapy, in contrast, can produce rapid relief—sometimes within days. That’s why some psychiatrists see it as a potential game-changer, especially for people with treatment-resistant depression. The NHS’s National Institute for Health and Care Excellence (NICE) is now reviewing the evidence to decide if psilocybin therapy should be approved for wider use. If it gives the green light, the NHS could start offering it in specialized clinics as early as 2026. That would make the UK one of the first countries in Europe to provide legal psychedelic therapy on the NHS. Still, there are big hurdles. Producing psilocybin for medical use is expensive and tightly controlled. Right now, most of it comes from licensed growers in the Netherlands, where psilocybin truffles are legal. Scaling up production to meet NHS demand won’t be easy. There’s also the question of cost. Each treatment session could run into the thousands, and the NHS would need to decide who gets access. ## What do patients and doctors think? For some, the idea of using a psychedelic drug to treat depression feels risky or even taboo. But many patients who’ve been through the trials say it saved their lives. One participant in the Imperial College study described feeling like they’d “reset” their brain. Others talk about gaining new perspectives on their lives and problems. Psychiatrists involved in the trials are cautiously optimistic but emphasize that this isn’t a quick fix. Dr. Robin Carhart-Harris, who led some of the early UK research, has said the therapy works best when paired with intensive psychological support. Without it, the benefits can fade. That’s why the NHS would likely only offer psilocybin therapy in tightly controlled settings with trained therapists. ## What’s next? The next few years will be critical. More trials are underway, including larger studies to confirm the early results and explore whether psilocybin can help with other conditions like PTSD or addiction. The NHS’s decision on whether to approve the treatment could set a precedent for other countries. For now, psilocybin therapy remains experimental, but it’s the closest it’s ever been to becoming a mainstream treatment. If the evidence holds up, it could offer a new way to help the millions of people in the UK living with depression who haven’t found relief in traditional therapies.

What You Need to Know

  • Source: BBC News
  • Published: May 17, 2026 at 16:18 UTC
  • Category: Environment
  • Topics: #bbc · #environment · #climate · #health · #research · #medicine

Read the Full Story

This is a curated summary. For the complete article, original data, quotes and full analysis:

Read the full story on BBC News →

All reporting rights belong to the respective author(s) at BBC News. GlobalBR News summarizes publicly available content to help readers discover the most relevant global news.

Curated by GlobalBR News · May 17, 2026

🇧🇷 Resumo em Português

O Reino Unido acelera os testes com “cogumelos mágicos” para combater a depressão e pode revolucionar o tratamento de saúde mental, colocando o país na vanguarda de uma terapia que soava improvável há poucos anos. Em 2022, os primeiros ensaios clínicos no sistema público britânico começaram a mostrar resultados promissores: pacientes com depressão grave apresentaram melhora significativa após uma ou duas sessões com psilocibina, o composto psicodélico presente em certos fungos. Agora, a discussão não é mais se a ciência funciona, mas se o Serviço Nacional de Saúde (NHS) deve incorporar essa abordagem ousada aos protocolos de saúde mental.

A relevância dessa notícia para o Brasil é direta, especialmente diante de uma crise nacional de saúde mental agravada pela pandemia, pelo desemprego e pela falta de acesso a tratamentos convencionais. Enquanto o Reino Unido estuda a viabilidade de integrar a terapia com psilocibina ao sistema público, o Brasil — que já enfrenta superlotação em hospitais psiquiátricos e uma legião de pacientes sem opções eficazes — precisa acompanhar de perto os desdobramentos dessa pesquisa. O debate também toca em questões legais e culturais: a substância ainda é ilegal no país, e a discussão sobre sua regulamentação médica poderia abrir caminho para tratamentos inovadores, mas exigiria uma revisão profunda na legislação de drogas.

Se os resultados se confirmarem, o Brasil poderia estar diante de uma oportunidade histórica para repensar a saúde mental — ou de um novo impasse ético e burocrático que atrasaria ainda mais a inovação no setor.